ES2589311T5 - Poblaciones de células que tienen actividad inmunorreguladora, método de aislamiento y usos - Google Patents

Poblaciones de células que tienen actividad inmunorreguladora, método de aislamiento y usos Download PDF

Info

Publication number
ES2589311T5
ES2589311T5 ES06777197T ES06777197T ES2589311T5 ES 2589311 T5 ES2589311 T5 ES 2589311T5 ES 06777197 T ES06777197 T ES 06777197T ES 06777197 T ES06777197 T ES 06777197T ES 2589311 T5 ES2589311 T5 ES 2589311T5
Authority
ES
Spain
Prior art keywords
cells
population
document
ifn
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES06777197T
Other languages
English (en)
Spanish (es)
Other versions
ES2589311T3 (es
Inventor
Dirk Büscher
De La Pena Manuel Angel Gonzalez
Mora Mario Delgado
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Superior de Investigaciones Cientificas CSIC
Tigenix SA
Original Assignee
Consejo Superior de Investigaciones Cientificas CSIC
Tigenix SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37708240&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2589311(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Consejo Superior de Investigaciones Cientificas CSIC, Tigenix SA filed Critical Consejo Superior de Investigaciones Cientificas CSIC
Application granted granted Critical
Publication of ES2589311T3 publication Critical patent/ES2589311T3/es
Publication of ES2589311T5 publication Critical patent/ES2589311T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES06777197T 2005-09-23 2006-09-22 Poblaciones de células que tienen actividad inmunorreguladora, método de aislamiento y usos Active ES2589311T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05077186 2005-09-23
EP05077186 2005-09-23
PCT/EP2006/009244 WO2007039150A2 (en) 2005-09-23 2006-09-22 Cell populations having immunoregulatory activity, method for isolation and uses

Publications (2)

Publication Number Publication Date
ES2589311T3 ES2589311T3 (es) 2016-11-11
ES2589311T5 true ES2589311T5 (es) 2020-02-14

Family

ID=37708240

Family Applications (2)

Application Number Title Priority Date Filing Date
ES06777197T Active ES2589311T5 (es) 2005-09-23 2006-09-22 Poblaciones de células que tienen actividad inmunorreguladora, método de aislamiento y usos
ES17154939T Active ES2751692T3 (es) 2005-09-23 2006-09-22 Poblaciones de células que tienen actividad inmunorreguladora, método de aislamiento y usos

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES17154939T Active ES2751692T3 (es) 2005-09-23 2006-09-22 Poblaciones de células que tienen actividad inmunorreguladora, método de aislamiento y usos

Country Status (19)

Country Link
US (5) US20090130067A1 (enExample)
EP (4) EP3184630B1 (enExample)
JP (2) JP5925408B2 (enExample)
KR (2) KR101536239B1 (enExample)
CN (2) CN101313062A (enExample)
AU (1) AU2006299144A1 (enExample)
CA (2) CA2623353C (enExample)
CY (1) CY1117972T1 (enExample)
DK (1) DK1926813T4 (enExample)
ES (2) ES2589311T5 (enExample)
HU (1) HUE030503T2 (enExample)
IL (3) IL190363A0 (enExample)
LT (1) LT1926813T (enExample)
MX (1) MX342474B (enExample)
PL (1) PL1926813T5 (enExample)
PT (1) PT1926813T (enExample)
SG (3) SG165418A1 (enExample)
SI (1) SI1926813T2 (enExample)
WO (1) WO2007039150A2 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
DK1926813T4 (da) 2005-09-23 2019-08-19 Tigenix S A U Cellepopulationer med immunregulatorisk aktivitet, fremgangsmåde til isolering og anvendelser
DK2347775T3 (da) 2005-12-13 2020-07-13 Harvard College Skabeloner til celletransplantation
US7989173B2 (en) 2006-12-27 2011-08-02 The Johns Hopkins University Detection and diagnosis of inflammatory disorders
EP2254602B1 (en) 2008-02-13 2018-11-21 President and Fellows of Harvard College Continuous cell programming devices
JP2011515470A (ja) 2008-03-28 2011-05-19 ステムサイト インコーポレーテッド 臍帯血細胞を用いた脳損傷の処置
CN102088994B (zh) * 2008-04-17 2014-06-25 海莱乌医院 基于吲哚胺2，3-双加氧酶的免疫疗法
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
AU2009201915C1 (en) 2008-08-22 2015-02-26 Regeneus Ltd Therapeutic methods
EP2204442A1 (en) * 2008-10-01 2010-07-07 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method of enriching stem cells in culture
GB0820397D0 (en) 2008-11-07 2008-12-17 Cellerix Sa Cells, nucleic acid constructs, cells comprising said constructs and methods utilizing said cells in the treatment of diseases
CN107007626A (zh) 2009-07-09 2017-08-04 蒂盖尼克斯公司 用于细胞治疗的方法和组合物
US8728456B2 (en) 2009-07-31 2014-05-20 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
AU2010286351A1 (en) 2009-08-31 2012-03-15 Amplimmune, Inc. B7-H4 fusion proteins and methods of use thereof
GB0918615D0 (en) 2009-10-23 2009-12-09 Cellerix Sa Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
US10130736B1 (en) 2010-05-14 2018-11-20 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US8883210B1 (en) 2010-05-14 2014-11-11 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
US9352003B1 (en) 2010-05-14 2016-05-31 Musculoskeletal Transplant Foundation Tissue-derived tissuegenic implants, and methods of fabricating and using same
PL2624873T3 (pl) 2010-10-06 2020-12-14 President And Fellows Of Harvard College Nadające się do wstrzykiwania hydrożele tworzące pory do terapii komórkowych opartych na materiałach
KR101900664B1 (ko) 2011-01-12 2018-09-21 타이제닉스, 에스.에이.유. 자가면역 및 염증성 질환에서 림프내 투여를 위한 지방-유래 중간엽 줄기 세포
EP2683813A1 (en) * 2011-03-11 2014-01-15 TiGenix, S.A.U. Cell populations having immunoregulatory activity, method for isolation and uses
CN103619177A (zh) * 2011-04-25 2014-03-05 南加州大学 通过抑制干扰素-γ和肿瘤坏死因子-α来改善组织再生的方法和组合物
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
US8834928B1 (en) 2011-05-16 2014-09-16 Musculoskeletal Transplant Foundation Tissue-derived tissugenic implants, and methods of fabricating and using same
KR20140071277A (ko) 2011-05-19 2014-06-11 타이제닉스, 에스.에이.유. 면역조절 활성을 갖는 세포 집단, 그의 제조 방법 및 용도
PL2838515T3 (pl) 2012-04-16 2020-06-29 President And Fellows Of Harvard College Kompozycje mezoporowatego krzemu do modulowania odpowiedzi odpornościowych
US20160120910A1 (en) * 2013-06-25 2016-05-05 Tigenix S.A.U. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof
MX2016001247A (es) 2013-07-30 2016-08-17 Musculoskeletal Transplant Foundation Matrices derivadas de tejido suave acelular y metodos para preparar las mismas.
JP6702866B2 (ja) 2013-11-18 2020-06-03 ルビウス セラピューティクス， インコーポレイテッド 合成膜−レシーバー複合体
RU2736495C2 (ru) * 2014-04-01 2020-11-17 Рубиус Терапьютикс, Инк. Способ и композиции для иммуномодуляции
CN107073090A (zh) 2014-04-30 2017-08-18 哈佛学院董事会 结合的疫苗装置和杀死癌细胞的方法
EP3160480B1 (en) 2014-06-30 2020-09-09 TiGenix, S.A.U. Mesenchymal stromal cells for treating rheumatoid arthritis
WO2016001846A1 (en) 2014-06-30 2016-01-07 Tigenix S.A.U. Mesenchymal stromal cells for treating sepsis
JP2016017068A (ja) * 2014-07-10 2016-02-01 国立大学法人金沢大学 脂肪組織由来間質細胞群を含む消化管炎症治療剤
KR101675521B1 (ko) * 2014-07-11 2016-11-17 대한민국 인돌아민 2,3-디옥시게나아제를 이용하여 인터페론-감마의 발현을 조절하는 방법
WO2016123573A1 (en) 2015-01-30 2016-08-04 President And Fellows Of Harvard College Peritumoral and intratumoral materials for cancer therapy
JP7094533B2 (ja) 2015-04-10 2022-07-04 プレジデント アンド フェローズ オブ ハーバード カレッジ 免疫細胞捕捉デバイスおよびその製造および使用方法
US10531957B2 (en) 2015-05-21 2020-01-14 Musculoskeletal Transplant Foundation Modified demineralized cortical bone fibers
US10912864B2 (en) 2015-07-24 2021-02-09 Musculoskeletal Transplant Foundation Acellular soft tissue-derived matrices and methods for preparing same
US11052175B2 (en) 2015-08-19 2021-07-06 Musculoskeletal Transplant Foundation Cartilage-derived implants and methods of making and using same
US11752238B2 (en) 2016-02-06 2023-09-12 President And Fellows Of Harvard College Recapitulating the hematopoietic niche to reconstitute immunity
WO2017144552A1 (en) 2016-02-22 2017-08-31 Centauri Biotech. S.L. Pharmaceutical or veterinary cell compositions comprising mesenchymal stromal cells (mscs) and dimethyl sulfoxide (dmso)
GB201604304D0 (en) 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
JP2019522486A (ja) 2016-07-13 2019-08-15 プレジデント アンド フェローズ オブ ハーバード カレッジ 抗原提示細胞模倣足場およびそれを作製および使用するための方法
KR102638898B1 (ko) 2016-08-02 2024-02-22 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 면역 반응을 조정하기 위한 생체재료
ES2977897T3 (es) 2017-03-15 2024-09-02 Orca Biosystems Inc Composiciones y métodos para trasplantes de células madre hematopoyéticas
WO2019174842A1 (en) 2018-03-13 2019-09-19 Oxacell Ag Cell products with improved stability and uses thereof
WO2019238952A1 (en) 2018-06-15 2019-12-19 Marinas Pardo Luis Pharmaceutical composition for dermatology and uses thereof
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
US12178833B2 (en) * 2019-05-21 2024-12-31 Emo Biomedicine Corp. Use of mesenchymal stem cells in treating immune-related diseases
US20230130155A1 (en) * 2020-01-30 2023-04-27 Modernatx, Inc. Mrnas encoding metabolic reprogramming polypeptides and uses thereof
KR102438419B1 (ko) * 2021-12-01 2022-09-01 메디포스트(주) Cd47 과발현 중간엽 줄기세포를 포함하는 폐 질환 예방 또는 치료용 조성물

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145770A (en) 1990-06-04 1992-09-08 Biosurface Technology, Inc. Cryopreservation of cultured epithelial sheets
US6010696A (en) 1990-11-16 2000-01-04 Osiris Therapeutics, Inc. Enhancing hematopoietic progenitor cell engraftment using mesenchymal stem cells
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5733542A (en) * 1990-11-16 1998-03-31 Haynesworth; Stephen E. Enhancing bone marrow engraftment using MSCS
US5709854A (en) 1993-04-30 1998-01-20 Massachusetts Institute Of Technology Tissue formation by injecting a cell-polymeric solution that gels in vivo
US6174333B1 (en) 1994-06-06 2001-01-16 Osiris Therapeutics, Inc. Biomatrix for soft tissue regeneration using mesenchymal stem cells
JPH10505250A (ja) 1994-06-06 1998-05-26 ケース ウエスターン リザーブ ユニバーシティ 組織再生のためのバイオマトリックス
DE69841850D1 (de) * 1997-12-02 2010-09-30 Artecel Sciences Inc Differenzierung in osteoblasten der fettgewebe-stromalen zellen und ihre verwendungen
WO1999029310A2 (en) 1997-12-05 1999-06-17 Medical College Of Georgia Research Institute, Inc. Regulation of t cell-mediated immunity by tryptophan and its analogs
US6514513B1 (en) 1998-02-04 2003-02-04 The General Hospital Corporation Costimulatory blockade and mixed chimerism in transplantation
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
US9585916B2 (en) 1999-03-26 2017-03-07 Northern Therapeutics Inc. Cell based therapy for the pulmonary system
DE69910362T2 (de) 1998-04-03 2004-06-24 Osiris Therapeutics, Inc. Anwendung der mesenchymalen stammzellen als immunsuppressiva
US20050153442A1 (en) 1999-03-10 2005-07-14 Adam Katz Adipose-derived stem cells and lattices
EP1165830B1 (en) 1999-03-10 2017-07-12 University of Pittsburgh of the Commonwealth System of Higher Education Adipose-derived stem cells and lattices
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
US20030082152A1 (en) 1999-03-10 2003-05-01 Hedrick Marc H. Adipose-derived stem cells and lattices
US7670628B2 (en) 1999-07-07 2010-03-02 Angioblast Systems, Inc. Mesenchymal precursor cell
US7078232B2 (en) 1999-08-19 2006-07-18 Artecel, Inc. Adipose tissue-derived adult stem or stromal cells for the repair of articular cartilage fractures and uses thereof
US6555374B1 (en) 1999-08-19 2003-04-29 Artecel Sciences, Inc. Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof
CA2392615A1 (en) 1999-12-06 2001-06-07 The General Hospital Corporation Pancreatic stem cells and their use in transplantation
CA2438904C (en) 2001-02-23 2012-09-04 The University Of Pittsburgh Rapid preparation of stem cell matrices for use in tissue and organ treatment and repair
EP1241249A1 (en) * 2001-03-12 2002-09-18 Gerold Schuler CD4+CD25+regulatory T cells from human blood
US20030054331A1 (en) 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
AU2002356935A1 (en) 2001-11-09 2003-05-19 Artecel Sciences, Inc. Methods and compositions for the use of stromal cells to support embryonic and adult stem cells
US7771716B2 (en) 2001-12-07 2010-08-10 Cytori Therapeutics, Inc. Methods of using regenerative cells in the treatment of musculoskeletal disorders
BR0207310A (pt) * 2001-12-18 2004-08-17 Mondobiotech Sa Composição farmacêutica de interferon gama ou de pirfenidona com diagnósticos moleculares para o melhor tratamento de doenças pulmonares intersticiais
EP1499347A2 (en) 2002-03-15 2005-01-26 Department of Veterans Affairs, Rehabilitation R&D Service Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs
DK1513877T3 (da) 2002-06-14 2008-06-02 Cartela Ab Markör for stamceller og dens anvendelse
US20040204458A1 (en) * 2002-08-16 2004-10-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of Lck inhibitors for treatment of immunologic diseases
US20040101959A1 (en) 2002-11-21 2004-05-27 Olga Marko Treatment of tissue with undifferentiated mesenchymal cells
CA2809195C (en) 2003-04-01 2014-05-20 United States Of America Department Of Veteran's Affairs Stem-cell, precursor cell, or target cell-based treatment of multi-organ failure and renal dysfunction
WO2004090095A2 (en) * 2003-04-01 2004-10-21 University Of Southern California Generation of human regulatory t cells by bacterial toxins for the treatment of inflammatory disorders
ES2265199B1 (es) * 2003-06-12 2008-02-01 Cellerix, S.L. Celulas madre adultas multipotentes procedentes de condrocitos desdiferenciados y sus aplicaciones.
AU2004252568B2 (en) 2003-06-27 2011-06-30 Ethicon, Incorporated Regeneration and repair of neural tissue using postpartum-derived cells
KR20060036933A (ko) 2003-10-07 2006-05-02 바이오마스터 인코포레이티드 지방-유래 전구세포의 세포 분화
JP4217262B2 (ja) 2003-11-04 2009-01-28 株式会社バイオマスター 脂肪組織から幹細胞を調製するための方法およびシステム
US7968126B2 (en) 2003-12-24 2011-06-28 The Trustees Of Columbia University In The City Of New York Creation of a biological atrioventricular bypass to compensate for atrioventricular block
AU2005206746B2 (en) * 2004-01-08 2008-08-28 Regents Of The University Of California Regulatory t cells suppress autoimmunity
US20080095749A1 (en) 2004-03-22 2008-04-24 Sudeepta Aggarwal Mesenchymal stem cells and uses therefor
EP2298863B1 (en) 2004-03-22 2015-07-22 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
RU2252252C1 (ru) 2004-04-09 2005-05-20 Тепляшин Александр Сергеевич Способ выделения мезенхимальных стволовых клеток
ES2264862B8 (es) 2004-08-25 2017-01-20 Cellerix, S.L. Biomaterial para sutura.
US20060045872A1 (en) * 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
ES2313805B1 (es) 2004-10-04 2009-12-23 Cellerix, S.L. Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral.
WO2006029347A2 (en) 2004-09-03 2006-03-16 University Of Maryland, Baltimore Integrin cd18 is a novel stromal stem cell marker and functions to promote osteogenesis
US20060286089A1 (en) 2005-04-08 2006-12-21 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
DK1926813T4 (da) 2005-09-23 2019-08-19 Tigenix S A U Cellepopulationer med immunregulatorisk aktivitet, fremgangsmåde til isolering og anvendelser
EP1795588A1 (en) 2005-12-07 2007-06-13 Cellerix, S.L. Use of adipose tissue derived mesenchymal stem cells for the treatment of graft versus host disease
WO2008036374A2 (en) 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
WO2009031606A1 (ja) 2007-09-07 2009-03-12 Jcr Pharmaceuticals Co., Ltd. 関節炎治療及び予防剤
EP3103463B1 (en) 2007-09-19 2020-01-01 Pluristem Ltd. Adherent cells from adipose or placenta tissues and use thereof in therapy
KR20100076031A (ko) 2007-10-17 2010-07-05 티엑셀 Ｔｒ１ 세포, 중간엽 줄기 세포 및 이들의 용도
GB0814249D0 (en) 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
ES2345867B1 (es) 2009-04-03 2011-07-28 Fundacion Instituto Mediterraneo Para La Biotecnologia Y La Investigacion Sanitaria (Imabis) Celulas madre multipotentes derivadas de estroma de mesenterio.
CN107007626A (zh) 2009-07-09 2017-08-04 蒂盖尼克斯公司 用于细胞治疗的方法和组合物
KR101900664B1 (ko) 2011-01-12 2018-09-21 타이제닉스, 에스.에이.유. 자가면역 및 염증성 질환에서 림프내 투여를 위한 지방-유래 중간엽 줄기 세포
EP2683813A1 (en) 2011-03-11 2014-01-15 TiGenix, S.A.U. Cell populations having immunoregulatory activity, method for isolation and uses
US20140134140A1 (en) 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections
JP6567430B2 (ja) 2013-03-15 2019-08-28 ティゲニクス、エセ、ア、ウＴｉＧｅｎｉｘ，Ｓ．Ａ．Ｕ． 細胞治療に対する臨床反応を決定するためのリンパ球バイオマーカー
US20160120910A1 (en) 2013-06-25 2016-05-05 Tigenix S.A.U. Cell populations having immunoregulatory activity, methods for the preparation and uses thereof

Also Published As

Publication number Publication date
CA2623353A1 (en) 2007-04-12
KR20140003631A (ko) 2014-01-09
US12186344B2 (en) 2025-01-07
CA2953782C (en) 2023-09-12
US20090130067A1 (en) 2009-05-21
CN101313062A (zh) 2008-11-26
US20170296593A1 (en) 2017-10-19
EP2340847B1 (en) 2025-11-05
AU2006299144A1 (en) 2007-04-12
PL1926813T5 (pl) 2019-11-29
IL246494B (en) 2021-09-30
WO2007039150A2 (en) 2007-04-12
EP2340847A2 (en) 2011-07-06
IL228670A (en) 2017-06-29
EP1926813A2 (en) 2008-06-04
SG10202001007TA (en) 2020-03-30
SI1926813T1 (sl) 2016-10-28
US20170296592A1 (en) 2017-10-19
SG165418A1 (en) 2010-10-28
DK1926813T4 (da) 2019-08-19
KR20080048555A (ko) 2008-06-02
IL228670A0 (en) 2013-12-31
ES2751692T3 (es) 2020-04-01
LT1926813T (lt) 2016-11-10
SI1926813T2 (sl) 2019-11-29
JP2014221045A (ja) 2014-11-27
CN107723274A (zh) 2018-02-23
US20150224146A1 (en) 2015-08-13
CA2953782A1 (en) 2007-04-12
JP5925408B2 (ja) 2016-05-25
CN107723274B (zh) 2021-05-07
DK1926813T3 (en) 2016-09-19
SG10201400793RA (en) 2014-08-28
IL246494A0 (en) 2016-08-31
HUE030503T2 (en) 2017-05-29
EP3184630A1 (en) 2017-06-28
EP2340847A3 (en) 2016-11-09
WO2007039150A3 (en) 2007-08-23
EP3184631B1 (en) 2020-08-12
CA2623353C (en) 2017-02-21
JP6089004B2 (ja) 2017-03-01
MX342474B (es) 2016-09-30
EP1926813B1 (en) 2016-06-08
EP3184631A1 (en) 2017-06-28
IL190363A0 (en) 2011-08-01
EP1926813B2 (en) 2019-05-22
CY1117972T1 (el) 2017-05-17
PL1926813T3 (pl) 2017-01-31
KR101536239B1 (ko) 2015-07-13
ES2589311T3 (es) 2016-11-11
JP2009508507A (ja) 2009-03-05
PT1926813T (pt) 2016-09-06
US20220313742A1 (en) 2022-10-06
EP3184630B1 (en) 2019-07-17
US9943550B2 (en) 2018-04-17

Similar Documents

Publication Publication Date Title
ES2589311T5 (es) Poblaciones de células que tienen actividad inmunorreguladora, método de aislamiento y usos
ES2479542T3 (es) Métodos y composiciones para su uso en terapias celulares
EP2663316A2 (en) Adipose-derived mesenchymal stem cells for intralymphatic administration in autoimmune and inflammatory diseases
AU2018253517B2 (en) Cell populations having immunoregulatory activity, method for isolation and uses
AU2012268272B2 (en) Cell populations having immunoregulatory activity, method for isolation and uses
MX2008003881A (en) Cell populations having immunoregulatory activity, method for isolation and uses
HK1239744A1 (en) Cell populations having immunoregulatory activity, method for isolation and uses
HK1158979A (en) Cell populations having immunoregulatory activity, method for isolation and uses
HK1124884A (en) Cell populations having immunoregulatory activity, method for isolation and uses